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Abstract
Background—Angiotensin II (Ang II) plays an important role in cardiovascular disease. It also 
leads to the activation of coagulation. The coagulation protease thrombin induces cellular 
responses by activating protease activated receptor 1 (PAR-1). We investigated if PAR-1 
contributes to Ang II-induced cardiovascular remodeling and inflammation.
Methods and Results—PAR-1+/+ (WT) and PAR-1−/− mice were infused with Ang II (600 
ng/kg/min) for up to 4 weeks. In WT mice, this dose of Ang II did not cause a significant increase 
in the blood pressure but caused pathological changes in both the aorta and heart. Ang II infusion 
resulted in vascular remodeling of the aorta demonstrated by a significant increase in medial wall 
thickening and perivascular fibrosis. Importantly, both parameters were significantly attenuated by 
PAR-1 deficiency. Furthermore, perivascular fibrosis around coronary vessels was reduced in Ang 
II-treated PAR-1−/− mice compared to WT mice. In addition, PAR-1 deficiency significantly 
attenuated the Ang II-induction of inflammatory cytokines and profibrotic genes in the aortas 
compared to WT mice. Finally, PAR-1 deficiency had no effect on Ang II-induced heart 
hypertrophy. However the heart function measured by fractional shortening, was less impaired in 
PAR-1−/− than in WT mice.
Conclusion—Our data indicated that PAR-1 plays a significant role in cardiovascular 
remodeling mediated by a blood pressure-independent action of Ang II.
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1. Introduction
The renin-angiotensin system (RAS) is a major contributor in the development and 
pathophysiology of hypertension (HTN) [1, 2]. The major consequences of HTN are end-
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organ damage and cardiovascular complications [1, 2]. Angiotensin II (Ang II) is the main 
mediator of the RAS. Ang II is generated by enzymatic cleavage of angiotensinogen to Ang 
I by the protease renin, with subsequent conversion of Ang I to Ang II by angiotensin 
converting enzyme (ACE) [1, 2]. In addition, chymase is the primary enzyme leading to this 
conversion in the heart [3]. Most of the effects of Ang II are mediated by angiotensin type 1 
(AT1) receptors [1, 2]. While the human genome only contains one AT1 receptor, there are 
two subtypes (AT1A and AT1B) in mice [4, 5]. AT1A appears to be the main receptor isoform 
regulating blood pressure (BP) whereas the specific function for AT1B is unclear [5]. AT1 
receptors are widely distributed and Ang II-dependent activation of this receptor affects the 
function of virtually all organs, including the vasculature and heart [1, 2]. Long-term 
exposure to Ang II leads to cardiovascular remodeling, fibrosis and heart hypertrophy [6, 7]. 
The mechanism of Ang II-induced heart remodeling may involve the direct action of Ang II 
on target tissues or be mediated by an Ang II-induced increase in BP [1, 2].
Ang II activation of the AT1 receptor also leads to upregulation of tissue factor (TF) 
expression. TF is the primary initiator of the coagulation cascade [8]. It is constitutively 
expressed in the blood vessel wall, as well as by cardiomyocytes and cardiac fibroblasts in 
the heart [9, 10]. Several in vitro studies demonstrated that Ang II induces TF expression in 
smooth muscle cells, endothelial cells and monocytes [7]. TF expression was also 
upregulated in the endothelium and media of blood vessels in hypertensive rats [11]. 
Moreover, blocking the AT1 receptor with valsartan inhibited the upregulation of TF 
expression [11]. Importantly, elevated levels of circulating TF were observed in patients with 
HTN, and AT1 receptor blockage significantly reduced TF activity [12, 13]. Recently, it was 
shown that Ang II infusion accelerated microvascular thrombosis in mice [14]. These data 
indicate that upregulation of TF expression during HTN is mediated via the AT1 receptor 
and may lead to systemic activation of the coagulation cascade.
Thrombin is the central protease of the coagulation cascade [15]. Human HTN patients and 
animal models of HTN showed enhanced thrombin generation in plasma as measured by 
elevated thrombin-antithrombin (TAT) complexes [16, 17]. In addition to its important role 
in both hemostasis and thrombosis, thrombin can induce multiple cellular responses via 
activation of protease activated receptors, such as PAR-1 [7, 15]. PAR-1 belongs to the 
family of seven transmembrane domain G protein–coupled receptors activated by proteolytic 
cleavage. PAR-1 is widely expressed within the vasculature and heart [7, 18, 19]. Studies by 
us and others showed that PAR-1 plays a significant role in the physiology and 
pathophysiology of the cardiovascular system [7, 20–23]. Several ex vivo studies 
documented that activation of PAR-1 induces endothelium-dependent relaxation in the aorta 
and coronary arteries [20, 22]. However, it has also been shown that activation of PAR-1 can 
elicit endothelium- or vascular smooth muscle-dependent vasoconstriction [20, 22]. These 
studies suggest that PAR-1-dependent vasoregulation may be cell/tissue specific. In mice, 
activation of PAR-1 with agonist peptide results in a biphasic BP response in which there is 
a rapid and transient hypotension followed by sustained HTN, presumably via activation of 
PAR-1 on smooth muscle cells [24]. Unstressed PAR-1−/− mice exhibit no obvious 
abnormalities in baseline BP compared to PAR-1+/+ mice [24, 25].
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In mouse and primate models of vascular injury, PAR-1 expression is upregulated in 
proliferating neointima [26, 27]. PAR-1 deficiency resulted in protection against vascular 
remodeling and stenosis in an endothelial denudation model of vascular injury [26]. 
Inhibition of PAR-1 with an anti-PAR-1 antibody or selective PAR-1 antagonist RWJ-59259 
in a balloon catheter-injury model also reduced smooth muscle cell proliferation, intimal 
area and thickness as well as percentage of stenosis [28, 29]. In vitro studies demonstrated 
that activation of PAR-1 with either thrombin or agonist peptide leads to a series of 
molecular and morphological changes that lead to hypertrophic growth of cardiomyocytes 
and proliferation of fibroblasts [30–32]. Recently, we showed that cardiomyocyte-specific 
overexpression of PAR-1 induced heart hypertrophy and decreased heart function via a TF-
dependent mechanism [23]. In addition, we and others have demonstrated that PAR-1 
contributes to cardiac remodeling in different heart injury models [7, 23, 33].
There are compelling data showing that Ang II leads to activation of coagulation which 
might contribute to disease progression.[7] We therefore analyzed the contribution of PAR-1 
signaling to Ang II-induced cardiac and vascular remodeling.
2. Material and Methods
2.1. Mice and Ang II infusion
PAR-1+/− mice were backcrossed at least 11 generations onto a C57Bl/6J background and 
bred to generate a PAR-1−/− and PAR-1+/+ littermate cousin line [23, 25, 34]. Male mice 
with an age between 8–12 weeks were used for all experiments. Mice were implanted with 
Alzet mini-osmotic pumps (Model 2004, DURECT Corporation) subcutaneously on the 
back of the neck. Infusion of Ang II (600 ng/kg/min, Sigma-Aldrich, St. Louis, MO) was 
performed for up to 28 days. The study was approved by the Office of Animal Care and Use 
at the University of North Carolina - Chapel Hill and complied with National Institute of 
Health guidelines.
2.2. Echocardiography and blood pressure measurements
Heart function was analyzed by echocardiography on conscious mice using a VisualSonics 
Vevo2100 system (VisualSonics, Toronto, ON) as previously described [34, 35]. End 
systolic and diastolic LV volume and LV wall dimension were measured digitally on M-
mode tracings and averaged from at least 4 cardiac cycles. FS was calculated from measured 
LV dimensions [23]. BPs were measured by the pressure-volume loop method with a 1.2 Fr 
admittance PV catheter (Sciscence, Ithaca, NY) on anesthetized and ventilated mice as 
described elsewhere [36]. All measurements were done in the UNC Rodent Advanced 
Surgical Models Core according to the American Society of Echocardiography guidelines.
2.3. Coagulation parameters
Blood was collected from the inferior vena cava into sodium citrate (final concentration, 
0.38%) and plasma separated by centrifugation (4,500 × g, 15 min, 4°C). Levels of TATc in 
plasma were quantified by ELISA (TAT Enzygnost Micro Kit; Dade Behring/Siemens) [34].
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2.4. Real-time PCR
Total mRNA from mouse hearts and aortas was isolated by the TriZol method [35, 37]. One 
µg total mRNA was reverse transcribed into cDNA and analyzed by real-time PCR using 
RealMasterMix and realplex2 Mastercycler (Eppendorf AG, Hamburg, Germany) [38]. To 
analyze the expression of interleukin (IL)-1β, CXCL1, CXCL2, transforming growth factor 
beta (TGFβ) 1, TGFβ3, connective tissue growth factor (CTGF), collagen (Coll) IaI, Coll 
Ia2 and Coll 3 mRNA we used predesigned probe sets (Integrated DNA Technologies, 
Coralville, IA). Variations in loading were adjusted using hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) mRNA expression.
2.5. Histology
Fibrosis and cellular infiltration was visualized on formalin-fixed, paraffin-embedded heart 
and aorta sections stained with Masson's Trichrome or H&E staining, respectively [10, 35, 
38]. Stained tissue sections were subsequently viewed using an Olympus BX51 microscope 
(Tokyo, Japan) and photographed using an Olympus DP70 digital camera with a DP 
controller and DP manager computer software [34, 35, 38].
2.6. Statistical analysis
All statistical analyses were performed using GraphPad Prism (version 5.04; GraphPad 
Software Inc., La Jolla, CA). Data are represented as mean ± SEM. For 2-group comparison 
of continuous data, 2-tailed Student’s t test was used. For multiple-group comparison, 
normally distributed data were analyzed by 1- or 2-way ANOVA and were Bonferroni 
corrected for repeated measures over time. A p-value ≤ 0.05 was regarded as significant.
3. Results
3.1. Infusion of Ang II leads to the systemic activation of coagulation and heart 
hypertrophy associated with cardiac fibrosis and inflammation
To determine if chronic AT1 receptor stimulation leads to cardiovascular remodeling and 
inflammation as well as activation of coagulation, WT mice were infused for up to 14 days 
with Ang II (600ng/kg/min). As expected, AT1 receptor stimulation in WT mice led to 
significant increase in heart weight: body weight (HW:BW) ratios 14 days of Ang II 
infusion (Figure 1A). Importantly, we also observe a systemic activation of coagulation 
measured by plasma TATc levels at day 14 after pump installation (Figure 1A). The 
increased heart hypertrophy and procoagulant state were associated with interstitial and 
perivascular fibrosis within the heart muscle (Figure 1B) and increased cellular infiltrations 
(Figure 1C) after 7 days of Ang II infusion. Our observation suggests that chronic activation 
of the AT1 receptor leads to activation of coagulation which was associated with pathologic 
cardiac fibrosis, inflammation and remodeling.
3.2. PAR-1 deficiency has no effect on blood pressure before and after Ang II infusion
To determine if PAR-1 activation contribute to the basal and Ang II dependent BP, BP in WT 
and PAR-1 deficient mice were measured before, 7 and 28 days after constant Ang II 
infusion. Consistently with previously published data, PAR-1 deficiency had no significant 
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effect on the baseline diastolic and systolic BP (Supplement 1) [24, 25]. Interestingly, 
infusion of Ang II at the concentration of 600ng/kg/min caused only modest but not 
statistically significant increase of BP in both WT and PAR-1−/− mice measured at day 7 and 
28 after initiation of infusion (Supplement 1). In addition, we did not find any differences 
between the genotypes with regards to the BP at day 7 and 28. This suggests that PAR-1 
does not play a major role in baseline BP regulation and that the all observations in our 
study were due to BP-independent AT1- and PAR-1-mediated signaling events in the setting 
resembling pre-HTN conditions [39].
3.3. PAR-1 deficiency attenuates Ang II-induced remodeling of the aorta
Ang II infusion into mice is known to lead to vascular remodeling in the aorta associated 
with an increased media thickness and enhanced fibrosis [6]. To determine if PAR-1 affects 
these parameters, media to lumen and fibrosis to lumen ratios of aortas were analyzed before 
and 28 days after Ang II infusion in WT and PAR-1 deficient mice. There were no 
significant differences with regard to aorta media thickness and the amount of fibrotic tissue 
around the aorta in mice of both genotypes before Ang II infusion (Figure 2). As expected, 
chronic AT1 stimulation for 28 days led to increase in aorta media thickness and increased 
collagen deposition visualized by Masson’s trichrome staining around the aorta in WT mice. 
Importantly both parameters were significantly attenuated in Ang II treated PAR-1−/− mice 
(Figure 2). These data suggest that PAR-1 dependent signaling pathways contribute to the 
vascular remodeling induced by chronic Ang II infusion.
3.4. Reduced expression of inflammatory and pro-fibrotic markers in the aortas of PAR-1 
deficient mice
To determine if changes in vascular remodeling induced by Ang II are associated with 
changes in the expression profile of inflammatory and pro-fibrotic genes in the aorta, real-
time PCR was performed on aorta samples of WT and PAR-1 deficient mice before, 7 and 
28 days after Ang II infusion. Importantly, there were no significant differences between the 
genotypes in the baseline mRNA expression levels in the aorta of the inflammatory 
mediators IL-1β, IL-6, TNF-α, MCP-1, CXCL1, and CXCL2 as well as pro-fibrotic 
mediators TGFβ1, TGFβ3, CTGF, and extracellular matrix components collagen Ia1, 
collagen Ia2 and collagen III (Figure 3 and data not shown). Except for CTGF, Ang II 
infusion led to a significant increase in the mRNA expression of all measured genes in WT 
mice at 7 days. Later at day 28, the aortic expression levels of the analyzed genes in WT 
mice returned to baseline with the exception of CTGF (Figure 3F). Importantly, PAR-1 
deficiency was associated with less pro-inflammatory and pro-fibrotic gene expression 
compared at day 7 as well as CTGF at day 28 (Figure 3). These data indicate that PAR-1 is 
involved in regulating a transient pro-inflammatory and pro-fibrotic phenotype leading to 
vascular inflammation and remodeling in the aorta during chronic Ang II infusion.
3.5. Ang II-induced perivascular fibrosis of coronary arteries is reduced in Ang II treated 
PAR-1 deficient mice
Besides its effect on the aorta, Ang II leads to perivascular fibrosis of coronary vessels and 
heart hypertrophy [6]. To analyze Ang II-dependent changes in perivascular fibrosis and 
cardiac remodeling, hearts of WT and PAR-1 deficient mice were analyzed before, 7 and 28 
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days after Ang II infusion. We did not observe any differences in the level of perivascular 
fibrosis around the cardiac arteries before Ang II infusion measured by fibrosis area to 
lumen area (Figure 4A). Chronic AT1 stimulation led to an increase of perivascular fibrosis 
around coronary arteries in both WT and PAR-1 deficient mice visualized by Masson’s 
trichrome staining of heart sections (Figure 4A). However, this parameter was significantly 
increased only in WT but not PAR-1−/− mice group at day 28 (Figure 4B). Next, we 
analyzed expression of CTGF in the heart which was shown to be associated with pathologic 
cardiac fibrosis and remodeling [38]. CTGF expression was significantly increased in the 
heart of WT mice 7 days after Ang II infusion and returned to the baseline (Figure 4 C) at 
day 28. Importantly, 7 days after Ang II infusion, CTGF mRNA expression was significantly 
lower in the heart of PAR-1 deficient mice compared to WT controls (Figure 4C).
3.6. PAR-1 deficient mice are protected against Ang II-induced heart dysfunction
Chronic AT1 stimulation is known to induce heart hypertrophy leading to heart dysfunction 
[40]. To analyze changes in heart hypertrophy, heart weight to body weight ratios were 
calculated in WT and PAR-1 deficient mice before and 28 days after Ang II infusion. PAR-1 
deficiency did not affect this parameter at baseline (Figure 4D). Heart weight to body weight 
ratios were significantly increased 28 days after Ang II infusion. However, PAR-1 deficiency 
did not affect the heart hypertrophy. Despite that, PAR-1 deficient mice had better preserved 
heart function compared to the WT mice 28 days after Ang II infusion (Figure 4E). This 
observation suggests that lack of PAR-1 dependent signaling protects against Ang II-induced 
heart dysfunction independently of heart hypertrophy.
4. Discussion
In this study, we demonstrated that PAR-1 deficiency attenuates pathologic Ang II-induced 
remodeling of the cardiovascular system. PAR-1 deficiency was associated with reduced 
mRNA expression of pro-inflammatory and pro-fibrotic markers which correlated with an 
attenuation of fibrosis and remodeling in the aortas of Ang II treated mice. In addition, we 
also observed reduced perivascular fibrosis of coronary vessels in hearts of PAR-1 deficient 
mice after of Ang II treatment. The reduced cardiac fibrosis in PAR-1 deficient mice led to a 
preserved heart function compared to Ang II treated WT mice. Interestingly, our observation 
was independent of a change in BP as well as heart hypertrophy since PAR-1 deficiency had 
no effect on these parameters. Our data indicate that PAR-1 plays a significant role in 
cardiovascular remodeling mediated by the BP-independent action of Ang II.
In our study, we were not able to detect increased BPs in anesthetized mice after 600 
ng/kg/min Ang II infusion. This was surprising since even a lower Ang II dose (490 ng/kg/
min) was shown to increase BP in telemetric observed animals [41]. However, the BP 
discrepancy might be due to the measurement used. Anesthesia has cardio-depressive effects 
leading to hypotension which might mask the real BP elevation in our experimental mice 
[42]. Thus, our study mimicked a murine pre-HTN model with BP below levels defined as 
HTN. Pre-HTN is described as BP between 120 and 139 mmHg systolic or 80 and 89 mm 
Hg diastolic [39]. It is thought that pre-HTN status adds a moderate-to-high risk to the total 
cardiovascular risk [39]. Importantly, the Framingham Heart study showed that patients with 
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pre-HTN have an increased risk to develop HTN [43]. Furthermore, the ATTICA study 
reported that there was an association between pre-HTN and increased inflammation, which 
was linked to the atherosclerotic process [39]. It was concluded that increased inflammation 
might be a mechanism in the initiation and/or progression of pre-HTN [44, 45].
The ongoing inflammation might be mediated by both the innate and adaptive immune 
processes. The innate immune pathway not only responds to exogenous pathogens but can 
be also activated by damage-associated molecular patterns (DAMPs) released endogenous 
by stressed, damaged or necrotic cells [46]. DAMPs are present in cardiovascular diseases 
during HTN [47]. AT1 activation was shown to induce p53-dependent apoptosis of cultured 
rat cardiomyocytes, which might lead the release of DAMPs [48]. Interestingly, Singh et al. 
reported that Ang II mediated cardiac hypertrophy and pro-inflammatory gene expression 
was mainly caused due to TRIF pathway activation [49]. The authors further showed that the 
expression of the TRIF-dependent cytokine CXCL10 was increased in MyD88−/− mice 
hearts but reduced in mice lacking TRIF signaling [49]. We found that PAR-1 stimulation 
enhanced toll-like receptor (TLR)-3/TRIF-dependent CXCL10 expression in cardiac 
fibroblasts and immune cells [34, 37]. This suggests that PAR-1 possibly enhanced 
pathologic TRIF signaling during Ang II infusion. Beside its effect on TLR signaling, 
PAR-1 activation induces the classical hallmarks of inflammation, including enhanced 
vascular permeability, upregulation of pro-inflammatory mediators and adhesion molecules 
[21]. In our study, we observed a PAR-1-dependent pro-inflammatory state in mice after 
Ang II infusion measured by increased IL-1β, IL-6, TNF-α, MCP-1, CXCL1 and CXCL2 
expression in the aorta. Consistent with this observation, a study showed that increased 
plasma levels of IL-1β, a cytokine involved in monocyte activation, precedes changes in BP 
in HTN [50]. Furthermore, IL-6, MCP-1 and especially TNF-α were shown to be essential 
for the pathologic effects of Ang II on the vasculature by increasing oxidative stress, 
activating fibroblasts and attracting T cells [47, 51].
Expression of pro-inflammatory cytokines is further linked to an induction of a pro-fibrotic 
phenotype. In addition, a mild-to-moderate increase in BP was reported to stimulate 
fibroblasts and increase collagen formation leading to a fibrotic remodeling of the 
myocardium with normal LV mass [52]. TGFβ1 mRNA and protein expression are increased 
in HTN patients [53]. CTGF has a role as a downstream mediator of the chronic fibrotic 
effects of TGFβ. Activated TGFβ induces CTGF expression in fibroblasts and 
cardiomyocytes [54]. During this process fibroblasts differentiate into myofibroblasts, the 
major cell that synthesizes collagen in cardiac remodeling [55, 56]. Activation of PAR-1 on 
fibroblasts induced cell proliferation and expression of pro-fibrotic genes [32, 57]. Here, we 
found increased CTGF and TGFβ as well as collagen expressions in Ang II infused WT but 
not in PAR-1−/− mice. This PAR-1-dependent pro-fibrotic phenotype resulted in increased 
vascular and perivascular remodeling associated with fibrosis and possible reduced elasticity 
of the aorta and coronary arteries. This is consistent with the finding of Celik and colleagues 
that pre-HTN was associated with an impairment of the aortic elasticity and inflammation 
when compared to healthy controls [44, 58]. These changes may lead to reduced coronary 
flow very early in pre-HTN before hypertrophy is apparent and thus may cause subsequently 
ischemia and fibrosis [59, 60]. Structural abnormalities are already seen in pre-HTN 
patients, although in a milder manner compared to newly diagnosed HTN patients which 
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might lead to cardiac remodeling [33, 61]. In our study, we did not observe any differences 
in the cardiac hypertrophy between the two genotypes. This was surprising since we and 
others have shown that PAR-1 contributes to cardiomyocyte hypertrophy and cardiac 
remodeling [23, 30]. However, the significant differences in fibrosis independent of 
hypertrophy might be due to the AT receptor distribution on cardiac fibroblasts and 
cardiomyocytes. Cardiomyocytes express comparable amounts of AT1 and AT2 receptors 
whereas fibroblasts express predominantly AT1 [62]. In addition, AT2 was shown to 
counteract AT1 activation [62]. Importantly, increased vascular inflammation as well as 
arterial stiffness was shown to be a predictive for cardiovascular events [63, 64].
The remaining question for further studies is the physiologic activator of PAR-1 in the 
setting of chronic Ang II infusion, AT1 stimulation, and HTN. The most likely candidate is 
thrombin. In our study, we observed increased TAT levels after chronic Ang II infusion. 
Consistent with our findings, it was shown that AT1 receptor stimulation and HTN was 
linked to increased activation of coagulation due to increased TF expression and thrombin 
generation [11–13, 16, 17], which led to a pro-thrombotic phenotype [14]. Another possible 
activator is the non-canonical activation of PAR-1 by matrix-metalloproteinases (MMPs) 1 
or 13 [7]. Recently, it was shown that MMP-1 enhanced Ang II induced vasoconstriction in 
endothelium-intact omental arteries in a PAR-1 dependent way ex vivo [65]. Furthermore, 
MMP-13 is expressed and active during Ang II induced HTN [66]. We showed that the 
MMP-13/PAR-1 pathways is active in cardiovascular diseases models [7, 18, 33, 34].
Importantly, besides its proven pathologic role, TF expressed by extravascular cells in the 
brain, lung and heart such as astrocytes, epithelial cells, smooth muscle cells, fibroblasts and 
cardiomyocytes maintains organ hemostasis [10, 11, 23, 67–71]. Reduced TF-dependent 
initiation of coagulation can result in hemorrhages, increased tissue fibrosis and reduced 
overall survival under healthy as well as pathologic conditions [10, 68, 71]. This dual role 
makes is difficult to use the TF blockage as viable therapy option [70]. Based on our data, 
further studies are warranted to investigate the effect of the PAR-1 inhibitor vorapaxar in 
Ang II-induced cardiovascular remodeling.
5. Conclusion
Taken together our data suggest that PAR-1 signaling pathway contributes to Ang II-induced 
cardiac fibrosis and heart dysfunction.
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Figure 1. Infusion of Ang II leads to cardiac hypertrophy, systemic activation of coagulation 
associated with cardiac fibrosis and inflammation
(A) Increase in heart weight to body weight ratios (HW:BW) and plasma levels of thrombin-
antithrombin complexes (TAT) in Ang II treated wild-type mice. (B) Masson’s trichrome 
staining of representative heart sections from control (left panel) and mice treated with Ang 
II for 7 days (middle and right panel). (C) Inflammatory cells are present in H&E stained 
heart sections from Ang II treated (right panel) but not from control mice (left panel). Bar = 
200 µm. Data (mean ± SEM; n = 3 for each time point) were analyzed by Student’s t-test. 
Statistical significances is shown as * P<0.05.
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Figure 2. PAR-1 deficiency attenuates Ang II-induced remodeling of aorta
(A) Representative cross sections of thoracic parts of aortas stained with Masson’s trichome. 
(B) Quantification of the media area and (C) fibrotic area to lumen area from PAR-1+/+ 
(white bars) and PAR-1−/− (black bars) mice aortas before and 28 days after constant Ang II 
infusion. Bar = 1 mm. Data (mean ± SEM; n = 5 for day 0, n =10 for day 28) were analyzed 
by 2-way ANOVA. Statistical significances is shown as # P<0.05 and * P<0.05 versus day 0 
of the respective genotype.
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Figure 3. Reduced expression of inflammatory and pro-fibrotic markers in the aortas of PAR-1 
deficient mice
Real-time PCR analysis of mRNA expression of inflammatory mediators (A) IL-1β, (B) 
CXCL1 (KC) and (C) CXCL2 (inflammatory protein 2-alpha, MIP-2α), of pro-fibrotic 
markers (D) transforming growth factor (TGF) β1, (E) TGFβ3 and (F) connective tissue 
growth factor (CTGF) as well as extracellular matrix proteins (G) collagen (Coll) Ia1, (H) 
Coll Ia2 and (I) Coll III in the aortas of PAR-1+/+ (white bars) and PAR-1−/− (black bars) 
mice before, 7 and 28 days of constant Ang II infusion. Data (mean ± SEM; n = 6–10) were 
analyzed by 2-way ANOVA. Statistical significances is shown as # P<0.05 and * P<0.05 
versus day 0 of the respective genotype.
Antoniak et al. Page 15
Cardiology. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. PAR-1 deficient mice are protected against Ang II-induced cardiac fibrosis and heart 
dysfunction
(A) Representative sections of heart coronary vessels from PAR-1+/+ and PAR-1−/− mice 
after 28 days of constant Ang II infusion stained with Masson’s trichrome. (B) 
Quantification of the fibrotic area to lumen area of heart coronary vessels from PAR-1+/+ 
(white bars) and PAR-1−/− (black bars) mice before and after 28 days of constant Ang II 
infusion. (C) Real-time PCR analysis of connective tissue growth factor (CTGF) mRNA 
expression in the heart of PAR-1+/+ and PAR-1−/− mice before, 7 and 28 days of continuous 
Ang II infusion. (D) Heart weight to body weight ratios (HW:BW) and (E) fractional 
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shortening measured by echocardiography before and 28 days of Ang II infusion. Bar = 200 
µm. Data (mean ± SEM; n = 6–10) were analyzed by 2-way ANOVA. Statistical 
significances is shown as # P<0.05 and * P<0.05 versus day 0 of the respective genotype.
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